id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-320067-929h6arn	Facheris, Paola	Complicated coronavirus disease 2019 (COVID‐19) in a psoriatic patient treated with ixekizumab	2020-06-18		.txt	text/plain	328	26	53	title: Complicated coronavirus disease 2019 (COVID‐19) in a psoriatic patient treated with ixekizumab The patient was hospitalized and treated with hydroxychloroquine 400 mg BID p.o. the first day followed by 200mg BID, ceftriaxone 1g BID IM, and noninvasive continuous positive airway pressure (CPAP) in courses of prone ventilation. The patient was discharged after 22 days, with 97% oxygen saturation on walking test. COVID-19 is caused by the SARS-CoV-2 virus, a new variant beta-coronavirus first isolated from the bronchoalveolar lavage fluid from patients with interstitial pneumonia. COVID-19 is characterized most commonly by fever and cough, although the clinical picture may range from completely asymptomatic to bilateral interstitial pneumonia. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Chinese Trial Clinical Registry.A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia	./cache/cord-320067-929h6arn.txt	./txt/cord-320067-929h6arn.txt